Table 3 Univariate and multivariate analysis for progression-free survival in the entire cohort.

From: The prognostic value of radiological and pathological lymph node status in patients with cervical cancer who underwent neoadjuvant chemotherapy and followed hysterectomy

Characteristics

Univariate analysis

Multivariate analysis

HR

95% CI

P value

HR

95% CI

P value

Age (≤ 50 vs. > 50)

0.820

0.394–1.705

0.597

   

NACT cycle (≤ 2 vs. > 2)

1.032

0.360–2.956

0.954

   

Baseline tumor size (≤ 4 vs. > 4)

3.010

1.050–8.633

0.040

   

Tumor size after NACT (≤ 4 vs. > 4)

1.930

0.881–4.227

0.100

   

Response to NACT (No vs. Yes)

0.537

0.262–1.100

0.089

   

FIGO stage (IB-IIB vs. IIIC)

3.739

1.708–8.186

 < 0.001

   

Tumor type (SCC vs. Non-SCC)

2.487

1.106–5.593

0.028

2.956

1.297–6.736

0.010

Differentiation (Well and moderately vs. Poorly)

3.249

1.587–6.654

0.001

2.370

1.130–4.970

0.022

LVSI (No vs. Yes)

4.525

2.101–9.744

 < 0.001

   

Stromal invasion depth (≤ 2/3 vs. > 2/3)

3.175

1.526–6.603

0.002

   

Perineural invasion (No vs. Yes)

1.875

0.651–5.398

0.244

   

Corpus involvement (No vs. Yes)

0.875

0.400–1.911

0.737

   

Vaginal involvement (No vs. Yes)

1.635

0.569–4.692

0.361

   

Incision margin (No vs. Yes)

3.966

1.198–13.125

0.024

   

Parametrial involvement (No vs. Yes)

4.701

1.638–13.491

0.004

   

Adjuvant radiation (No vs. Yes)

4.882

1.867–12.766

0.001

3.266

1.183–9.019

0.022

Adjuvant chemotherapy (No vs. Yes)

0.696

0.095–5.116

0.722

   

LNr (No vs. Yes)

3.154

1.538–6.469

0.002

   

LNp (No vs. Yes)

6.226

3.009–12.882

 < 0.001

3.777

1.715–8.319

 < 0.001

  1. HR hazard ratio, CI confidence interval, NACT neoadjuvant chemotherapy, FIGO The International Federation of Gynecology and Obstetrics, SCC squamous cell carcinoma, LVSI lymph-vascular space invasion, LNr radiological lymph node status, LNp pathological lymph node status.
Back to article page